Whether you are a pharmaceutical manufacturer, medical device company, nutraceutical producer or healthcare investor, this Knowledge Center provides practical insight into Iraq's registration requirements, regulatory framework, market dynamics and distribution models — prepared so that you can make informed decisions before you commit.
The full pathway after the June 2025 change: requirements, time ceilings that terminate files, legalisation, pricing exposure, and the maintenance rules that suspend registrations every year.
Market size, import dependence, underserved therapeutic segments, and the two channels — KIMADIA and the private sector — that define commercial reach.
Pricing assessed too late, documentation gaps, exclusivity granted too early, partners without regulatory capability, and weak distribution strategy.
Document-by-document requirements, validity windows, and the legalisation chain.
How public-sector procurement works, and how it differs from registration.
LSR obligations, reporting systems, and PV audit readiness.
What 1,800 registered companies and 12,600 products reveal about the market.
If you are evaluating Iraq — or you have already tried and hit a wall — one conversation changes the picture.
Contact an Expert